AlzeCure Pharma Feed

2026-10-27 18:30:00 AlzeCure Pharma announces change of CEO ahead of next phase of development 6,52 SEK | +0,93% | 2,76 MSEK

2026-10-27 18:30:00 AlzeCure Pharma genomför VD-byte inför nästa utvecklingsfas 6,52 SEK | +0,93% | 2,76 MSEK

2026-10-08 10:00:00 AlzeCure Pharma presenterar hos Aktiespararna i Stockholm den 14 oktober 6,74 SEK | -2,32% | 0,51 MSEK

2026-10-08 10:00:00 AlzeCure Pharma to present at Aktiespararna in Stockholm on 14 October 6,74 SEK | -2,32% | 0,51 MSEK

2026-10-07 10:00:00 AlzeCure Pharma to present at Redeye Neurology Day on October 15 6,90 SEK | +1,47% | 0,99 MSEK

2026-10-07 10:00:00 AlzeCure Pharma presenterar på Redeye Neurology Day den 15 oktober 6,90 SEK | +1,47% | 0,99 MSEK

2026-09-22 10:00:00 AlzeCure Pharma to present at Swiss Nordic Bio 2026 in Zurich 7,60 SEK | +1,33% | 1,34 MSEK

2026-09-22 10:00:00 AlzeCure Pharma presenterar på Swiss Nordic Bio 2026 i Zürich 7,60 SEK | +1,33% | 1,34 MSEK

2026-09-18 12:30:00 AlzeCure Pharma publicerar uppdaterad bolagspresentation efter avtalen med Eli Lilly och QuantumCell 7,74 SEK | -0,26% | 1,65 MSEK

2026-09-18 12:30:00 AlzeCure Pharma publishes updated company presentation following the Eli Lilly and QuantumCell agreements 7,74 SEK | -0,26% | 1,65 MSEK

2026-09-08 10:00:00 AlzeCure Pharma to present at Aktiedagen in Stockholm on September 15 8,44 SEK | +0,72% | 3,79 MSEK

2026-09-08 10:00:00 AlzeCure Pharma presenterar på Aktiedagen i Stockholm den 15 september 8,44 SEK | +0,72% | 3,79 MSEK

2026-08-27 10:00:00 AlzeCure Pharma to present at the Pareto Securities 17th Annual Healthcare Conference on September 2 7,68 SEK | +22,29% | 14,3 MSEK

2026-08-27 10:00:00 AlzeCure Pharma presenterar på Pareto Securities 17th Annual Healthcare Conference den 2 september 7,68 SEK | +22,29% | 14,3 MSEK

2026-08-26 08:00:00 AlzeCure publishes its interim report for January – June 2026 6,28 SEK | -1,88% | 2,90 MSEK

2026-08-26 08:00:00 AlzeCure offentliggör delårsrapport för januari – juni 2026 6,28 SEK | -1,88% | 2,90 MSEK

2026-08-18 10:00:00 AlzeCure receives a USD 10 million upfront payment and completes initial transaction with Lilly 6,72 SEK | -0,30% | 3,02 MSEK

2026-08-18 10:00:00 AlzeCure erhåller upfront-betalning om 10 miljoner USD och slutför den initiala transaktionen med Lilly 6,72 SEK | -0,30% | 3,02 MSEK

2026-08-12 10:00:00 AlzeCure receives a total upfront payment of USD 12 million and completes the initial transaction with QuantumCell 6,72 SEK | -1,75% | 3,61 MSEK

2026-08-12 10:00:00 AlzeCure får totalt 12 miljoner USD i upfront-betalning och slutför den initiala transaktionen med QuantumCell 6,72 SEK | -1,75% | 3,61 MSEK

2026-08-03 08:00:00 AlzeCure Pharma resolves on a directed share issue to QuantumCell 6,18 SEK | +1,64% | 1,33 MSEK

2026-08-03 08:00:00 AlzeCure Pharma beslutar om riktad nyemission till QuantumCell 6,18 SEK | +1,64% | 1,33 MSEK

2026-07-02 08:00:00 Final outcome of AlzeCure’s rights issue 6,90 SEK | +11,29% | 20,7 MSEK

2026-07-02 08:00:00 Utfall i AlzeCures företrädesemission 6,90 SEK | +11,29% | 20,7 MSEK

2026-07-01 07:00:00 AlzeCure Pharma ingår utlicensierings- och samarbetsavtal med QuantumCell ApS för NeuroRestore-projektet ACD856 6,20 SEK | +60,21% | 42,4 MSEK

2026-07-01 07:00:00 AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project 6,20 SEK | +60,21% | 42,4 MSEK

2026-06-29 17:30:00 Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026 3,87 SEK | -0,51% | 0,98 MSEK

2026-06-29 17:30:00 Kommuniké från årsstämma i AlzeCure Pharma den 29 juni 2026 3,87 SEK | -0,51% | 0,98 MSEK

2026-06-16 10:00:00 Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's 3,78 SEK | -4,55% | 5,68 MSEK

2026-06-16 10:00:00 Positiva resultat i den kliniska fas Ib-studien med NeuroRestore ACD856 som utvecklas mot Alzheimers 3,78 SEK | -4,55% | 5,68 MSEK

2026-06-16 08:00:00 The subscription period in AlzeCure Pharma's Rights Issue begins today 3,78 SEK | -4,55% | 5,68 MSEK

2026-06-16 08:00:00 Idag börjar teckningsperioden i AlzeCure Pharmas företrädesemission 3,78 SEK | -4,55% | 5,68 MSEK

2026-06-09 07:10:00 AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project 4,20 SEK | +246,57% | 80,7 MSEK

2026-06-09 07:10:00 AlzeCure Pharma ingår samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt 4,20 SEK | +246,57% | 80,7 MSEK

2026-06-05 08:00:00 AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document 1,18 SEK | -1,46% | 0,14 MSEK

2026-06-05 08:00:00 AlzeCure Pharma genomför tidigare aviserad företrädesemission om ca 30,1 MSEK och offentliggör informationsdokument 1,18 SEK | -1,46% | 0,14 MSEK

2026-05-26 08:00:00 NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB 1,18 SEK | -2,89% | 0,35 MSEK

2026-05-26 08:00:00 KALLELSE TILL ÅRSSTÄMMA I ALZECURE PHARMA AB 1,18 SEK | -2,89% | 0,35 MSEK

2026-05-19 10:00:00 AlzeCure Pharma livesänder seminarium om smärtprojektet TrkA-NAM ACD137 med fokus på artros och nervsmärta 1,23 SEK | +0,36% | 0,03 MSEK

2026-05-19 10:00:00 AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain 1,23 SEK | +0,36% | 0,03 MSEK

2026-05-13 12:00:00 AlzeCure Pharma to present at Redeye Investor Forum Online on May 21 1,28 SEK | +4,29% | 0,18 MSEK

2026-05-13 12:00:00 AlzeCure Pharma presenterar på Redeye Investor Forum Online den 21 maj 1,28 SEK | +4,29% | 0,18 MSEK

2026-05-13 10:00:00 AlzeCure Pharma presenterar på ABG Investor Days den 21 maj 1,28 SEK | +4,29% | 0,18 MSEK

2026-05-13 10:00:00 AlzeCure Pharma to present at ABG Investor Days on May 21 1,28 SEK | +4,29% | 0,18 MSEK

2026-05-06 10:00:00 New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain 1,20 SEK | -2,14% | 0,71 MSEK

2026-05-06 10:00:00 Ny vetenskaplig artikel publicerad om TrkA-NAM ACD137 mot osteoartros smärta 1,20 SEK | -2,14% | 0,71 MSEK

2026-05-05 08:00:00 AlzeCure publishes its interim report for January – March 2026 1,23 SEK | -1,06% | 0,01 MSEK

2026-05-05 08:00:00 AlzeCure offentliggör delårsrapport för januari – mars 2026 1,23 SEK | -1,06% | 0,01 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode